The self-insured employer is, in theory, the most sophisticated buyer in American healthcare. It bears the full financial risk of its employees’ medical and pharmacy utilization, has every incentive to manage costs aggressively, and has access to claims data that in principle allows granular analysis of its spending. In practice, most large employers cannot tell you with confidence what they are paying for pharmacy benefits, who is retaining how much of the manufacturer rebates generated by their employees’ prescriptions, or whether their PBM’s formulary decisions are optimizing their employees’ health outcomes or the PBM’s margin. This is not ignorance. It is the predictable result of a contracting environment that the intermediaries who benefit from opacity have had decades to refine.
The Anatomy of PBM Opacity
The pharmacy benefit manager sits between the employer and virtually every other actor in the drug supply chain — manufacturers, wholesalers, pharmacies, and patients — and extracts value from each of those relationships in ways that are contractually obscured from the employer. The traditional PBM revenue model includes the retained spread between what it pays pharmacies for drugs and what it charges the plan, the portion of manufacturer rebates it retains rather than passing through, administrative fees, and a range of other remuneration categories that the industry has collectively branded “direct and indirect remuneration” (DIR fees). The Consolidated Appropriations Act of 2021′, transparency requirements have created new disclosure obligations for some of these revenue streams, but the translation of disclosed information into actionable employer understanding requires analytical capacity that many HR and benefits teams do not possess.
The problem is compounded by the contractual complexity of PBM agreements, which are among the most negotiated and litigated commercial contracts in American healthcare. PBM contracts are typically several hundred pages, include definitions of key terms that are specific to each contract and may not align with industry norms, and are governed by audit rights that are often narrowly scoped and practically difficult to exercise. The KFF Employer Health Benefits Survey has tracked the growth of self-insurance adoption over the past two decades, but the survey data cannot capture whether self-insured employers are actually exercising the cost management advantages that self-insurance theoretically provides.
The Drug Mix Shift Problem
Employer pharmacy spend has been reshaped over the past decade by the shift toward specialty drugs — biologics, gene therapies, and other high-cost agents that account for a small fraction of prescription volume but a rapidly growing majority of pharmacy expenditure. The actuarial implications of this shift are substantial. A plan that once managed pharmacy costs primarily through generic substitution and formulary tier design now faces a spend concentration problem in which a handful of patients on specialty drugs can determine whether the plan finishes the year in surplus or deficit. Standard PBM contracting tools — formulary tiers, prior authorization, step therapy — apply to specialty drugs in attenuated form, because the clinical complexity and the limited availability of therapeutic alternatives constrain substitution strategies.
The specialty drug spend concentration problem also exposes a design flaw in how most employer health plans are structured for risk management. An employer with five thousand covered lives and one employee who requires a CAR-T therapy at a cost of several hundred thousand dollars faces an actuarial shock that its risk management framework was not designed to absorb. Stop-loss insurance — the reinsurance product that self-insured employers purchase to cap their per-employee exposure — typically covers costs above a specific threshold but does not address the fundamental problem that specialty drug utilization is unpredictable, low-probability, and high-severity in exactly the pattern that is hardest to manage through conventional actuarial tools.
The Strategic Response
Employers that have made the most progress on pharmacy cost management share a common characteristic: they have moved from a passive, ASO-model relationship with their PBM toward an active governance posture that includes explicit contracting for pass-through pricing, third-party contract audits, clinical pharmacy program oversight, and in some cases direct manufacturer contracting for high-cost specialty drugs. The Business Group on Health’s annual survey consistently identifies pharmacy cost management as the top priority for large employers, and the strategies that large employers are deploying have become markedly more sophisticated over the past five years. But large employers represent a minority of the self-insured market. The median self-insured employer — with two hundred to two thousand covered lives, limited benefits staff, and strong dependence on its broker and TPA for contracting expertise — remains largely in the position that the PBM contracting environment was designed to sustain: paying more than it needs to, for a service whose actual economics it cannot independently verify.
